RxDoctor Payments Data

Jennifer Schmidt, DO

Family Medicine · Cary, NCNPI 1982676540

Payments from drug & device makers

$4,937in general payments, 2019–2025

Across 283 payments — averaging $17.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$447
  • Lilly USA, LLC$394
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$268
  • Currax Pharmaceuticals LLC$161
  • AstraZeneca$161
  • plus $1K from 29 others

What the payments were for

  • Food & beverage$4,928100%
  • Education$90%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,937 in reported general payments places this provider in the 85th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$23,888
Medicare patients
58
Services billed
300

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide87$110,607
MounjaroTirzepatide64$68,584
JardianceEmpagliflozin28$27,786
SynthroidLevothyroxine Sodium44$2,790
Bupropion XlBupropion Hcl41$2,259
Levothyroxine Sodium103$2,155
Liothyronine Sodium38$1,259
Cevimeline Hcl12$1,253
Gabapentin29$843
Ezetimibe23$774
Ibandronate Sodium22$730
Losartan Potassium56$706
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine12$565
Fluoxetine Hcl43$544
Atorvastatin Calcium77$541

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$2,300$110,60787 claims
Lilly USA, LLCMounjaro$394$68,58464 claims
Boehringer IngelheimJardiance$33$27,78628 claims
AbbVieSynthroid$447$2,79044 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$33$2,155103 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Cary

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →